Results 51 to 60 of about 131 (88)
ABSTRACT. Dengue remains a major public health challenge in Brazil, with recurrent outbreaks placing a strain on healthcare systems. The TAK-003 vaccine offers a promising control strategy, particularly for children. This cross-sectional study evaluated the seroprevalence of anti-dengue IgG in 643 children and adolescents aged 4–16 ...
Bortuluzi, Amanda Maria Miguel +8 more
openaire +2 more sources
This research applied a predictive model to analyse the role that vaccination and community factors play in controlling the dengue virus. The study considers epidemiological and environmental data from the city of São Paulo (Brazil) after the start of ...
Wenru Wang +11 more
doaj +1 more source
BackgroundThe evolutionary dynamics of dengue virus type 1 (DENV-1) in non-endemic settings such as southeastern coastal China where outbreaks predominantly stem from imported cases, remains insufficiently defined, particularly in relation to lineage ...
Tianran Zhang +13 more
doaj +1 more source
Background: In trials, dengue vaccine efficacy evaluation relies on participants presenting with febrile illness/clinically suspected dengue contacting the study site for sample collection and clinical assessment within a short timeframe.
Harald Pfaar +8 more
doaj +1 more source
Introduction: Dynamic transmission models are commonly used to evaluate the impact of vaccination as they capture both direct and indirect effects; however, they tend to be complex and computationally intensive.
Elizaveta Kharitonova +6 more
doaj +1 more source
Abstract Background A safe and effective vaccine that can be universally administered would represent a major advance in efforts to control dengue. Takeda’s TAK-003 is a potential candidate for such a vaccine. However, phase-III trial results suggest that TAK-003 confers differential protection by outcome, serotype, and ...
Manar Alkuzweny +2 more
openaire +2 more sources
Background: Dengue fever remains a major health risk, with 100 to 400 million clinical cases occurring each year. TAK-003 a tetravalent live-attenuated vaccine, offers potential protection against all four dengue virus (DENV) serotypes (DENV-1, DENV-2, DENV-3, DENV-4), providing a new option for travelers to dengue-endemic areas.
Sikora, Agnieszka Weronika +1 more
openaire +1 more source
Opportunities and challenges of mRNA technologies in development of dengue virus vaccine
Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF)
Xiaoyang Liu
doaj +1 more source
ABSTRACT This descriptive observational study based on post‐marketing surveillance data evaluates adverse events following immunization (AEFI) associated with the TAK‐003 (Qdenga®) vaccine. Conducted in Dourados, Brazil, between January and November 2024, the study aimed to assess the frequency, nature, and severity of AEFI to inform ...
Luana Clemm Kuhnen Anschau +9 more
openaire +3 more sources
Segurança e Eficácia da Vacina Qdenga® (TAK-003) em Crianças de Até 12 anos
Introdução: A dengue, uma doença viral transmitida pelo mosquito Aedes aegypti, representa um desafio significativo para a saúde pública, especialmente no Brasil, onde ocorre uma epidemia. A vacina Qdenga (TAK-003) surge como uma promissora intervenção, considerando sua segurança e eficácia potencial.
Gabriel dos Santos Medeiros +12 more
openaire +1 more source

